What Gilead's Quarter ended Sep 30, 2026 10-Q says: 6 signals
Gilead filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition announced, acquisition completed and bookings decline.
Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn
Get Gilead's live signals in Claude or ChatGPT, or by API
What changed at Gilead this week? Use Autobound signals for gilead.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 14
Source: Autobound Signal API · 68 signals tracked for Gilead · updated
10-Q · latest 10
What Gilead's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 6 signals
Gilead completed acquisitions of Arcellx for $7.0B, Tubulis for $3.1B, and Ouro Medicines
During the nine months ended September 30, 2026, Gilead completed the acquisitions of Arcellx, Tubulis, and Ouro Medicines, recording billions in acquired IPR&D expenses.
$7B
Arcellx acquisition acquired IPR&D expense
Gilead records $1.75 billion IPR&D impairment following discontinuation of Phase 3 EVOKE-03 study
Gilead recognized an impairment charge of $1.75 billion for the NSCLC IPR&D intangible asset after discontinuing its Phase 3 EVOKE-03 study evaluating Trodelvy.
$1.8B
impairment charge of NSCLC IPR&D intangible asset
Gilead received FDA approval for Bixlenvo and Hepcludex, plus expanded Trodelvy indications
Gilead received FDA approval for Bixlenvo for HIV and accelerated approval for Hepcludex for chronic HDV in the U.S., along with new approvals for Trodelvy in mTNBC.
Veklury product sales plunge 69% in Q3 2026 due to lower hospitalization rates
Veklury sales fell 69% to $86 million in Q3 2026 compared to $277 million in Q3 2025, driven by lower rates of COVID-19-related hospitalizations.
$86M
Veklury product sales for the three months ended September 30, 2026
-69%
decrease in Veklury sales for the three months ended September 30, 2026
Gilead deploys multi-year enterprise resource planning (ERP) system rollout across organization
Gilead disclosed an ongoing deployment of an enterprise resource planning system and related systems scheduled in phases over the next few years.
enterprise resource planning systemERP
Gilead announced definitive agreement to acquire oral IL-23R program from PepStar Therapeutics
Gilead entered into an agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited.
- SEC EDGAR
10-Q
Filed · 5 signals
Gilead highlights recent appointment of Chief Medical Officer Dietmar Berger.
The company filed an offer letter for Dietmar Berger, indicating a key addition to the clinical leadership team.
Wells Fargo, National AssociationComputershare Trust Company, National Association
The filing of a severance agreement for Deborah Telman (former General Counsel) points to a recent major change in the legal department's leadership.
Wells Fargo, National AssociationComputershare Trust Company, National Association
Gilead faces tax examinations and disputes with IRS and authorities in Germany & Ireland.
The company is under examination by the U.S.
Gilead executes capital restructuring with new debt issuance and a $6B stock buyback authorization.
Gilead issued new senior notes in May 2026 and has over $6 billion remaining in its stock repurchase authorization as of June 2026.
$6B
Approximate dollar value of shares that may yet be purchased under stock repurchase programs.
Wells FargoComputershare Trust Company
Earlier 10-Q filings
- 10-QFiled · 3 signalsSEC EDGAR
Showing 10 of 14 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Gilead earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Facing complex logistics and reimbursement hurdles for new Yeztugo launch.The launch of the new injectable drug, Yeztugo, involves navigating complex payer coverage, reimbursement processes, and logistical challenges like "white bagging," creating a need for solutions that streamline patient journey management and provider integration. | |
| Raised full-year revenue guidance, citing strong HIV portfolio performanceThe company increased its full-year HIV revenue growth guidance from 3% to 5% and raised the low end of its total product sales range. This financial outperformance and confidence indicates strong cash flow and budget availability for strategic initiatives. | |
| Achieved record market share for key HIV drugs Biktarvy and DescovyFlagship HIV products Biktarvy and Descovy for PrEP reached record market shares of 52% and 45% respectively. This strong commercial momentum creates a need for investment in sales enablement, marketing automation, and data analytics to defend and expand this leadership position. | |
| Struggling to lower hurdles for community adoption of cell therapies.Despite expanding treatment centers, the company acknowledges that 'we have more to do' to lower barriers for community adoption of its complex cell therapies. This indicates a need for solutions related to provider education, patient logistics, and simplifying treatment workflows. | |
| Emphasizing disciplined operating expense management and business model leverage.Leadership repeatedly highlighted 'disciplined operating expense management' and 'operating expense discipline' as key contributors to financial performance. This signals a strong corporate mandate and appetite for technologies and services that can drive efficiency and reduce costs. | |
| New liver disease drug Livdelzi achieved 35% sequential growthThe liver disease drug Livdelzi grew 35% sequentially, surpassing $100 million in quarterly sales for the first time. This rapid growth in a new franchise indicates strong market uptake and creates budget opportunities for solutions that can support and scale this high-performing product line. |
Signal API · MCP
Track Gilead with the Signal API
One POST /v1/companies/enrich call with gilead.com returns Gilead 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Gilead 10-Q
When did Gilead file its latest 10-Q?
What did Gilead disclose in its latest 10-Q?
What did Gilead say on its recent earnings calls?
Where can I read Gilead's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .